… Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal
transplantation. Nat Commun 2019;10:4712. https://doi.org/10.1038/s41467-019-12628-1 60. …

… inhibitor (CNI) toxicity or cancer, rejection or primary kidney disease recurrence, anatomic
… Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal …

… TME and discuss strategies targeting abnormal metabolic … improves the therapeutic effect
of PD-1 blockade antibody [31]. … In phase I clinical trial of patients with renal cell cancer, …

… LT) after receiving PD-1 blockade combined targeted therapy, … of left lobe, cysts in right
kidney. Besides, he also provided … could effectively relieve toxicity of PD-1 blockade (31). The …

… PD-1/PD-L1 inhibitors, however, are generally less toxic and … innate cells may contribute to
ICI efficacy and toxicity [62, 63]. … in one case study of a renal transplant patient who developed …

… Synchronous effects of oxidative stress, uncoupled biosynthesis … simultaneously reduced
the toxicity of navitoclax [88]. … of PD-1 or two ligands by antibodies is referred to as PD-1 therapy…

… frequently observed tumors in kidney transplant recipients (KTRs; … by the ICI target, which
was 33.3% (30/90) for PD-1, 40.0% (6… outcomes for anti–PD-1 toxicity and efficacy in the SOTR …

… ) not only to uncouple the efficacy and toxicity of antibodies targeting PD-1, but also to …
patient with a renal allograft could justify the novel use of an mTOR inhibitor in combination …

… LDH activity are related to the baseline of anti-PD-1 therapy. … receiving TNFα blockade
under PD1-targeted ICI therapy … with preserved anti-cancer efficacy by blockade of TNFα as a …

… efficacy of ICI in these two cancer types. In order to assess … to uncouple anti-cancer and
anti-allograft immune response. … incidence of acute kidney injury compared with anti-PD-1. This …